Nektar Therapeutics
NKTR58.760USD
+7.690+15.06%
Close 09/18, 16:00（ET）Quotes delayed by 15 min
731.99MMarket Cap
LossP/E TTM
More Details of Nektar Therapeutics Company
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
Company Info
Ticker SymbolNKTR
Company nameNektar Therapeutics
IPO dateMay 03, 1994
CEOMr. Howard W. Robin
Number of employees61
Security typeOrdinary Share
Fiscal year-endMay 03
Address455 Mission Bay Boulevard South
CitySAN FRANCISCO
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code94158
Phone18554826587
Websitehttps://www.nektar.com/
Ticker SymbolNKTR
IPO dateMay 03, 1994
CEOMr. Howard W. Robin
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Howard W. Robin
Mr. Howard W. Robin
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
41.83K
-32.35%
Dr. Jonathan Zalevsky, Ph.D.
Dr. Jonathan Zalevsky, Ph.D.
Senior Vice President, Chief Research and Development Officer
Senior Vice President, Chief Research and Development Officer
15.15K
-12.71%
Mr. Jeffrey Robert (Jeff) Ajer
Mr. Jeffrey Robert (Jeff) Ajer
Independent Director
Independent Director
2.28K
--
Dr. Diana M. Brainard, M.D.
Dr. Diana M. Brainard, M.D.
Independent Director
Independent Director
--
--
Mr. R. Scott Greer
Mr. R. Scott Greer
Independent Director
Independent Director
--
--
Mr. Robert B. (Rob) Chess
Mr. Robert B. (Rob) Chess
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Sandra A. Gardiner
Ms. Sandra A. Gardiner
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Mr. Mark A. Wilson, J.D.
Mr. Mark A. Wilson, J.D.
Senior Vice President, Chief Legal Officer
Senior Vice President, Chief Legal Officer
--
--
Mr. Corey Davis
Mr. Corey Davis
Managing Director
Managing Director
--
--
Mr. Roy A. Whitfield
Mr. Roy A. Whitfield
Lead Independent Director
Lead Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Howard W. Robin
Mr. Howard W. Robin
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
41.83K
-32.35%
Dr. Jonathan Zalevsky, Ph.D.
Dr. Jonathan Zalevsky, Ph.D.
Senior Vice President, Chief Research and Development Officer
Senior Vice President, Chief Research and Development Officer
15.15K
-12.71%
Mr. Jeffrey Robert (Jeff) Ajer
Mr. Jeffrey Robert (Jeff) Ajer
Independent Director
Independent Director
2.28K
--
Dr. Diana M. Brainard, M.D.
Dr. Diana M. Brainard, M.D.
Independent Director
Independent Director
--
--
Mr. R. Scott Greer
Mr. R. Scott Greer
Independent Director
Independent Director
--
--
Mr. Robert B. (Rob) Chess
Mr. Robert B. (Rob) Chess
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
No Data
By RegionUSD
Name
Revenue
Proportion
Rest of world
97.05M
98.60%
United States
1.38M
1.40%
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, Sep 10
Updated: Wed, Sep 10
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BVF Partners L.P.
6.71%
The Vanguard Group, Inc.
3.84%
Nantahala Capital Management, LLC
3.73%
Millennium Management LLC
3.41%
AQR Capital Management, LLC
2.25%
Other
80.06%
Shareholders
Shareholders
Proportion
BVF Partners L.P.
6.71%
The Vanguard Group, Inc.
3.84%
Nantahala Capital Management, LLC
3.73%
Millennium Management LLC
3.41%
AQR Capital Management, LLC
2.25%
Other
80.06%
Shareholder Types
Shareholders
Proportion
Hedge Fund
22.42%
Investment Advisor
14.24%
Investment Advisor/Hedge Fund
9.72%
Research Firm
1.82%
Individual Investor
0.71%
Family Office
0.23%
Venture Capital
0.08%
Pension Fund
0.01%
Other
50.76%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
342
8.92M
53.56%
-2.95M
2025Q1
408
8.48M
68.15%
-4.47M
2024Q4
427
136.20M
73.84%
-69.28M
2024Q3
442
143.71M
78.07%
-57.20M
2024Q2
458
138.43M
75.38%
-54.08M
2024Q1
477
115.32M
62.79%
-91.21M
2023Q4
499
122.94M
64.45%
-94.24M
2023Q3
522
148.15M
77.94%
-68.45M
2023Q2
531
142.56M
75.34%
-88.27M
2023Q1
545
178.73M
94.47%
-35.40M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
820.65K
4.92%
-1.22K
-0.15%
Mar 31, 2025
Nantahala Capital Management, LLC
519.27K
3.12%
-1.40K
-0.27%
Mar 31, 2025
Millennium Management LLC
932.86K
5.6%
+780.28K
+511.36%
Jun 27, 2025
AQR Capital Management, LLC
242.72K
1.46%
+187.17K
+336.95%
Mar 31, 2025
Acadian Asset Management LLC
486.78K
2.92%
+6.71K
+1.40%
Mar 31, 2025
PRIMECAP Management Company
356.97K
2.14%
-12.39K
-3.35%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
873.88K
5.24%
-15.04K
-1.69%
Mar 31, 2025
TCG Crossover Management, LLC
266.67K
1.6%
--
--
Mar 31, 2025
View more
Related ETFs
Updated: Tue, Sep 2
Updated: Tue, Sep 2
Name
Proportion
Invesco NASDAQ Future Gen 200 ETF
0.9%
Simplify Health Care ETF
0.84%
Fidelity Enhanced Small Cap ETF
0.04%
Invesco RAFI US 1500 Small-Mid ETF
0.03%
Schwab U.S. Small-Cap ETF
0.01%
iShares Biotechnology ETF
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 Value ETF
0%
Proshares Ultra Russell 2000
0%
ProShares Ultra Nasdaq Biotechnology
0%
View more
Invesco NASDAQ Future Gen 200 ETF
Proportion0.9%
Simplify Health Care ETF
Proportion0.84%
Fidelity Enhanced Small Cap ETF
Proportion0.04%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.03%
Schwab U.S. Small-Cap ETF
Proportion0.01%
iShares Biotechnology ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
ProShares Ultra Nasdaq Biotechnology
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
